Preclinical assessment of a recombinant RBD-Fc fusion protein as SARS-CoV-2 candidate vaccine
Authors:
Open Access
- 11 September 2024
- journal article
- research article
- Published by Akademiai Kiado Zrt. in European Journal of Microbiology and Immunology
- Vol. 14 (3) , 228-242
Abstract
Background: Waning immunity and emergence of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), highlight the need for further research in vaccine development.Methods: A recombinant fusion protein containing the receptor-binding domain (RBD) fused to the human IgG1 Fc (RBD-Fc) was produced in CHO-K1 cells. RBD-Fc was emulsified with four adjuvants to evaluate its immunogenicity. The RBD-specific humoral and cellular immune responses were assessed by ELISA. The virus neutralizing potency of the vaccine was investigated using four neutralization methods. Safety was studied in mice and rabbits, and Antibody-Dependent Enhancement (ADE) effects were investigated by flow cytometry.Results: RBD-Fc emulsified in Alum induced a high titer of anti-RBD antibodies with remarkable efficacy in neutralizing both pseudotyped and live SARS-CoV-2 Delta variant. The neutralization potency dropped significantly in response to the Omicron variant. RBD-Fc induced both TH2 and particularly TH1 immune responses. Histopathologic examinations demonstrated no substantial pathologic changes in different organs. No changes in serum biochemical and hematologic parameters were observed. ADE effect was not observed following immunization with RBD-Fc.Conclusion: RBD-Fc elicits highly robust neutralizing antibodies and cellular immune responses, with no adverse effects. Therefore, it could be considered a promising and safe subunit vaccine against SARS-CoV-2.Keywords
Funding Information
- Tehran University of Medical Sciences (1401-1-99-57094)
This publication has 82 references indexed in Scilit:
- Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated miceVaccine, 2011
- Adjuvant-Free Immunization with Hemagglutinin-Fc Fusion Proteins as an Approach to Influenza VaccinesJournal of Virology, 2011
- Efficient mucosal vaccination mediated by the neonatal Fc receptorNature Biotechnology, 2011
- Vaccine-induced enhancement of viral infectionsVaccine, 2009
- Polarizing a T-cell responseNature, 2004
- IL-13 and IFN-γ Secretion by Activated T Cells in HIV-1 Infection Associated with Viral Suppression and a Lack of Disease ProgressionThe Journal of Immunology, 1999
- Feline immunodeficiency virus subunit vaccines that induce virus neutralising antibodies but no protection against challenge infectionVaccine, 1998
- Monoclonal antibody analysis of neutralization and antibody-dependent enhancement of feline infectious peritonitis virusJournal of Virology, 1992
- Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophagesJournal of Virology, 1992
- Antibody-mediated enhancement of disease in feline infectious peritonitis: Comparisons with dengue hemorrhagic feverComparative Immunology, Microbiology and Infectious Diseases, 1981